{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:25:01Z","timestamp":1789205101900,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1016\/j.jconrel.2009.08.017","type":"journal-article","created":{"date-parts":[[2009,8,24]],"date-time":"2009-08-24T08:08:36Z","timestamp":1251101316000},"page":"95-99","source":"Crossref","is-referenced-by-count":32,"title":["Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles"],"prefix":"10.1016","volume":"140","author":[{"given":"Ju Yen","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Blatchford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Tetley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Duf\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2009.08.017_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ijc.23689","article-title":"Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs","volume":"123","author":"Constantinou","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jconrel.2009.08.017_bib2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.canlet.2008.03.063","article-title":"Multitargeted therapy of cancer by tocotrienol","volume":"269","author":"Nesaretnam","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2009.08.017_bib3","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.canlet.2005.06.036","article-title":"Tumor suppressive effects of tocotrienol in vivo and in vitro","volume":"229","author":"Wada","year":"2005","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jconrel.2009.08.017_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jnutbio.2008.09.003","article-title":"Antiangiogenic and anticancer potential of unsaturated vitamin E (tocotrienol)","volume":"20","author":"Miyazawa","year":"2009","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jconrel.2009.08.017_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.clim.2006.06.006","article-title":"The transferrin receptor part II : targeted delivery of therapeutic agents into cancer cells","volume":"121","author":"Daniels","year":"2006","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2009.08.017_bib6","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bcmd.2007.02.003","article-title":"Transferrin receptor 2 is frequently expressed in human cancer cell lines","volume":"39","author":"Calzolari","year":"2007","journal-title":"Blood Cells Mol. Diseases"},{"key":"10.1016\/j.jconrel.2009.08.017_bib7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0168-3659(92)90086-7","article-title":"The tumor blood vessel as an ideal target for macromolecular anticancer agents","volume":"19","author":"Maeda","year":"1992","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2009.08.017_bib8","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jconrel.2009.08.017_bib9","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1023\/A:1026422915326","article-title":"Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting","volume":"17","author":"Duf\u00e8s","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2009.08.017_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/B:PHAM.0000012156.65125.01","article-title":"Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles","volume":"21","author":"Duf\u00e8s","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2009.08.017_bib11","first-page":"4435","article-title":"Effects of the pH dependence of 3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide-formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay","volume":"49","author":"Plumb","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2009.08.017_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.jconrel.2009.08.017_bib13","first-page":"3752","article-title":"Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size","volume":"55","author":"Yuan","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2009.08.017_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0378-5173(99)00256-2","article-title":"Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice","volume":"193","author":"Ishida","year":"1999","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2009.08.017_bib15","first-page":"4440","article-title":"Hyperthermia enables tumor-specific nanoparticle delivery: effect of particle size","volume":"60","author":"Kong","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2009.08.017_bib16","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0065-2660(08)60152-2","article-title":"Pharmaceutical perspectives of nonviral gene therapy","volume":"41","author":"Mahato","year":"1999","journal-title":"Adv. Genet."},{"key":"10.1016\/j.jconrel.2009.08.017_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1525-1373.2000.22434.x","article-title":"Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells","volume":"224","author":"McIntyre","year":"2000","journal-title":"Proc. Soc. Exp. Biol. Med."}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836590900580X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836590900580X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T17:50:10Z","timestamp":1545069010000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836590900580X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["S016836590900580X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2009.08.017","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}